Tenax Therapeutics (TENX) versus Its Competitors Head to Head Contrast

Tenax Therapeutics (NASDAQ: TENX) is one of 32 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its competitors? We will compare Tenax Therapeutics to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.

Risk and Volatility

Tenax Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Tenax Therapeutics’ competitors have a beta of 3.58, meaning that their average stock price is 258% more volatile than the S&P 500.



Analyst Recommendations

This is a breakdown of current recommendations for Tenax Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics 0 0 0 0 N/A
Tenax Therapeutics Competitors 172 715 1524 70 2.60

As a group, “Commercial physical research” companies have a potential upside of 11.08%. Given Tenax Therapeutics’ competitors higher probable upside, analysts plainly believe Tenax Therapeutics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Tenax Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tenax Therapeutics N/A -$6.81 million -0.15
Tenax Therapeutics Competitors $1.22 billion $42.30 million 17.27

Tenax Therapeutics’ competitors have higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

16.3% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 45.7% of shares of all “Commercial physical research” companies are owned by institutional investors. 10.4% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 15.9% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tenax Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tenax Therapeutics N/A -175.30% -156.52%
Tenax Therapeutics Competitors -264.40% -15.96% -9.71%

Summary

Tenax Therapeutics competitors beat Tenax Therapeutics on 9 of the 10 factors compared.

About Tenax Therapeutics

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.